Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study

Christoph K. Naber, Stylianos A. Pyxaras, Holger Nef, Alexander J. IJsselmuiden, Carlo Briguori, Christian Schlundt, Joanna Wykrzykowska, Franz R. Eberli, Helge Möllmann, S. ren Galatius, Johannes Rieber, Philippe Commeau, Robert-Jan van Geuns, David Bouchez, Harald Mudra

Research output: Contribution to journalArticleAcademicpeer-review


Aims: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice. Methods and results: The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%). Conclusions: The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.
Original languageEnglish
Pages (from-to)356-358
Issue number3
Publication statusPublished - 1 Jun 2016

Cite this